TABLE 2.

irAEs with ipilimumab plus nivolumab^a

Event	Grade 1–2	Grade 3–4	Grade 5	Total (n = 32)
Pneumonitis	2 (6%)	2 (6%)	0	4 (13%)
Colitis/esophagitis	2 (6%)	2 (6%)	0	4 (13%)
Autoimmune hepatitis	1 (3%)	1 (3%)	1 (3%)	3 (9%)
Rash	3 (9%)	0	0	3 (9%)
Arthritis	1 (3%)	0	0	1 (3%)
Myocarditis	0	1 (3%)	0	1 (3%)

^aSelect percentages may not add up to 100% due rounding.